跳转至内容
Merck
CN

H1200000

氢氯噻嗪

European Pharmacopoeia (EP) Reference Standard

登录查看公司和协议定价

别名:
6-氯-3,4-二氢-2H-1,2,4-苯并噻二嗪-7-磺酰胺1,1-二氧化物, 6-氯-7-磺酰胺-3,4-二氢-1,2,4-苯并噻二嗪-1,1-二氧化物
经验公式(希尔记法):
C7H8ClN3O4S2
CAS号:
分子量:
297.74
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

hydrochlorothiazide

制造商/商品名称

EDQM

应用

pharmaceutical (small molecule)

格式

neat

储存温度

2-8°C

SMILES字符串

NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1Cl

InChI

1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)

InChI key

JZUFKLXOESDKRF-UHFFFAOYSA-N

基因信息

human ... SLC12A3(6559)

正在寻找类似产品? 访问 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Hydrochlorothiazide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

生化/生理作用

碳酸酐酶抑制剂

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

象形图

Health hazard

警示用语:

Warning

危险声明

危险分类

Carc. 2

WGK

WGK 2

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

监管及禁止进口产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Soham Rej et al.
Drugs & aging, 31(12), 911-916 (2014-10-22)
Little is known about how lithium should be dosed to achieve therapeutic but safe serum concentrations in older adults. In this paper, we investigate how the lithium dose-concentration ratio changes across the lifespan. This was a cross-sectional analysis of 63
Dragos Vinereanu et al.
American heart journal, 168(4), 446-456 (2014-09-30)
The objective of this study is to compare the effects of 2 types of diuretics, indapamide and hydrochlorothiazide, added to an angiotensin-converting enzyme inhibitor, on ventricular and arterial functions in patients with hypertension and diabetes. This is a prospective, randomized
James J DiNicolantonio
Expert opinion on pharmacotherapy, 13(6), 807-814 (2012-03-20)
Hydrochlorothiazide (HCTZ) has not been shown to reduce mortality or cardiovascular events when given as a single agent. In fact, HCTZ increased cardiovascular death and coronary artery disease (CAD) compared to placebo and usual care in 2 randomized trials, yet
Sverre E Kjeldsen et al.
Journal of clinical hypertension (Greenwich, Conn.), 15(6), 380-388 (2013-06-05)
Older patients frequently receive angiotensin II receptor blocker/diuretic combinations to control blood pressure (BP), although there have been relatively few trials specifically examining this patient population. A pooled analysis was performed of data from 7 randomized trials of telmisartan/hydrochlorothiazide combinations
Franz H Messerli et al.
The American journal of medicine, 124(10), 896-899 (2011-10-04)
Hydrochlorothiazide (HCTZ) has become by far the most commonly prescribed antihypertensive drug in the US. In 2008, 47.8 million prescriptions were written for HCTZ alone and 87.1 million prescriptions for HCTZ combinations. However, there is no evidence that HCTZ in

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门